Liver News and Research

RSS

Average annual incidence of sepsis varies depending on method used

Though the toll of sepsis is known to be enormous - it is estimated to cost the U.S. health care system $24.3 billion each year, and is the nation's third-leading killer, behind heart disease and cancer - the true magnitude of incidence of and death from the illness remains unknown.

16 Apr 2013

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.

16 Apr 2013

Taking too much vitamin E not real health concern, expert says

Despite concerns that have been expressed about possible health risks from high intake of vitamin E, a new review concludes that biological mechanisms exist to routinely eliminate excess levels of the vitamin, and they make it almost impossible to take a harmful amount.

16 Apr 2013

Study on targeted liver cancer therapy called SIR-Spheres microspheres completes patient recruitment

Australian-based global oncology company, Sirtex Medical Limited (ASX: SRX), has announced the completion of patient recruitment for its global SIRFLOX clinical study which is aimed at expanding the clinical use of its SIR-spheres® microspheres targeted radiation therapy from a last line medical treatment to a standard first-line oncology therapy.

16 Apr 2013

New nanosponge safely removes dangerous toxins from bloodstream

Engineers at the University of California, San Diego have invented a "nanosponge" capable of safely removing a broad class of dangerous toxins from the bloodstream - including toxins produced by MRSA, E. coli, poisonous snakes and bees.

15 Apr 2013

Microwave ablation therapy reduces pain in patients with painful bone, soft-tissue tumors

First-of-its-kind research presented today showed microwave ablation therapy cut pain in half for patients with painful bone and soft-tissue tumors and took less time to complete than radiofrequency ablation.

15 Apr 2013

Pharmacological study shows interactions between drugs can be detected with minute doses

Clinical pharmacologists at Heidelberg University Hospital have achieved major progress for improving the reliability of drugs. In a pharmacological study, they showed for the first time that interactions between drugs can be detected with minute doses in the range of nanograms.

15 Apr 2013

Study reveals inner workings of master regulator that controls diverse functions

New discoveries by a team of scientists at LSU Health Sciences Center New Orleans for the first time reveal the inner workings of a master regulator that controls functions as diverse as the ability of nerve cells to "rewire" themselves in response to external stimuli and the mechanism by which certain viruses hijack normal cellular processes to facilitate their replication that can ultimately lead to cancer. The research will be published in the April 12, 2013 issue of the Journal of Biological Chemistry.

12 Apr 2013

Researchers identify new potential therapeutic target for lowering cholesterol

Researchers at the University of Michigan have identified a new potential therapeutic target for lowering cholesterol that could be an alternative or complementary therapy to statins.

12 Apr 2013

Nalmefene can provide important clinical benefit for alcohol-dependent patients

A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.

12 Apr 2013

New research shows safety can be improved for people participating in medical experiments

In almost 90 per cent of cases, novel drugs tested on humans by pharmaceutical companies do not work as intended and must be scrapped. Often the drugs do not work, while at worst, test subjects die. New research from the University of Southern Denmark now shows that this number can be reduced.

12 Apr 2013

MKK4 gene could be a promising therapeutic target for liver disease, study reveals

Chronic liver failure is a major health problem that causes about one million deaths around the world each year. A study published April 11th by Cell Press in the journal Cell reveals a new type of screen for identifying genes that promote liver repair in mouse models of both acute and chronic liver disease.

12 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Newly discovered mouse viruses can pave the way for future progress in hepatitis research

Newly discovered mouse viruses could pave the way for future progress in hepatitis research, enabling scientists to study human disease and vaccines in the ultimate lab animal.

9 Apr 2013

New hospital gown blends style for patient with clinical function

The drafty backside is finally gone, replaced with comfort, warmth and dignity in a newly designed hospital gown that blends style for the patient with clinical function for the health care team.

9 Apr 2013

Liver News and Research

Average annual incidence of sepsis varies depending on method used

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Taking too much vitamin E not real health concern, expert says

Study on targeted liver cancer therapy called SIR-Spheres microspheres completes patient recruitment

New nanosponge safely removes dangerous toxins from bloodstream

Microwave ablation therapy reduces pain in patients with painful bone, soft-tissue tumors

Pharmacological study shows interactions between drugs can be detected with minute doses

Study reveals inner workings of master regulator that controls diverse functions

Researchers identify new potential therapeutic target for lowering cholesterol

Nalmefene can provide important clinical benefit for alcohol-dependent patients

New research shows safety can be improved for people participating in medical experiments

MKK4 gene could be a promising therapeutic target for liver disease, study reveals

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Researchers evaluate Pexa-Vec to slow progression of liver cancer

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Newly discovered mouse viruses can pave the way for future progress in hepatitis research

New hospital gown blends style for patient with clinical function

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News